Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Kyowa Kirin Co., Ltd.

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible.

The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together, we work as a collaborative team to understand clinical needs and advance innovations that have a profound impact on patient lives. 

Our growth in North America relies on entrepreneurial team players who are willing to share their expertise and ideas in an environment that prioritizes innovation, diversity, integrity and “wa.” Each person plays a significant role in shaping the work we do and the results we deliver.

Kyowa Kirin, Inc.- U.S.

Our company is excited to join the NC biopharma community, and looks forward to sharing more plans soon.  https://bit.ly/49MSwrq

Did you know that there are over 6,000 distinct rare conditions, currently affecting about 300 million people worldwide and it takes approximately five years on average for rare disease patients to get a diagnosis?

At Kyowa Kirin, we engage with and listen closely to our external environment, so as we approach #RareDiseaseDay, we wanted to shine a light on the stories of those affected by rare diseases. 

#KKIMakingPeopleSmile #RareDiseaseMonth

Doug Grant, our General Manager for Canada, reflects on what the timely access to care means for those patients living with #raredisease.  

#RareDiseaseDay #ShowYourStripes

Kyowa Kirin is constantly seeking ways to meet the needs of those we serve, no matter where they are in the world. Hear from our global Kyowa Kirin leaders about how our Commitment to Life mission statement is rooted within our organization and helps us deliver on our promise to bring more smiles to those living with a #raredisease. 

#KKIMakingPeopleSmile

Everyone should have a chance to live life to the fullest. This #RareDiseaseDay, Kyowa Kirin joins the rare community in advocating for equitable access to timely diagnosis, treatment, and care for people living with rare diseases.

#RareDiseaseMonth #ShareYourRare #ShowYourStripes #ShowYourColours

Kyowa Kirin is proud to sponsor #RareDiseaseDay through National Organization for Rare Disorders. Together we seek to raise awareness of the challenges millions of rare disease patients face.

#RareDiseaseMonth #ShareYourRare #ShowYourColours

Had a wonderful time with Kyowa Kirin, Inc.- U.S. colleagues at last night’s BioNJ Annual Dinner, celebrating many accomplished and dedicated leaders working on behalf of patients. Congrats to my old colleague, Mark Peters  II, for being honored - and continuing to inspire so many others!
And thanks Debbie Hart 👏👏


Tara D'Orsi Greg Palko RPh, MBA Kevin Lynch

This International Day of Women and Girls in Science we celebrate the innovation and fresh perspectives that women and girls bring to scientific discovery.

Listen as our own Rachel Soloff, Ph.D., Executive Director of Research reflects on what drove her to choose a #STEM career. 

Today and every day, we welcome people to join us who share our commitment to making a profound impact on patients’ lives: https://bit.ly/49bVjL4

#WomenInScience #IDWGS

Throughout #RareDiseaseMonth, and every day of the year, we remain steadfast in our commitment to the #raredisease community. We are constantly seeking ways to meet the needs of the people we serve, no matter where they are in the world, and will work endlessly to develop new, innovative technologies to help bring smiles to those living with a rare disease.

#KKIMakingPeopleSmile #ProfoundImpact

Kyowa Kirin Co., Ltd. 
Kyowa Kirin Asia Pacific 
Kyowa Kirin International plc.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	340.61B -	333.45B 2.10%	364.32B 9.26%	343.02B 5.85%	353.38B 3.02%	346.53B 1.94%	305.82B 11.75%	318.35B 4.10%	352.25B 10.65%	398.37B 13.09%	442.23B 11.01%
cost of revenue	127.85B -	127.54B 0.24%	138.92B 8.92%	134.53B 3.16%	129.06B 4.06%	119.34B 7.53%	79.62B 33.28%	80.44B 1.03%	87.85B 9.21%	86.92B 1.06%	121.61B 39.92%
gross profit	212.76B -	205.90B 3.22%	225.39B 9.47%	208.49B 7.50%	224.32B 7.59%	227.19B 1.28%	226.20B 0.44%	237.91B 5.18%	264.40B 11.13%	311.46B 17.80%	320.62B 2.94%
selling and marketing expenses	16.42B -	15.96B 2.78%	16.71B 4.69%	15.86B 5.13%			24.03B -	30.28B 25.98%
general and administrative expenses	205M -	169M 17.56%			112.96B -	119.81B 6.06%	117.32B 2.08%	126.61B 7.92%	145.61B 15.01%	166.19B 14.13%
selling general and administrative expenses	16.42B -	15.96B 2.78%	16.71B 4.69%	15.86B 5.13%	112.96B 612.39%	119.81B 6.06%	117.32B 2.08%	126.61B 7.92%	145.61B 15.01%	166.19B 14.13%	152.67B 8.13%
research and development expenses	43.63B -	47.67B 9.25%	51.52B 8.08%	53.79B 4.41%	49.16B 8.62%	48.59B 1.15%	53.51B 10.13%	52.31B 2.24%	57.68B 10.26%	62.90B 9.04%	72.11B 14.64%
other expenses	-392M -	-141M 64.03%	255M 280.85%	753M 195.29%	-1.76B 333.33%	15.50B 982.13%	-14.58B 194.09%	-9.19B 36.97%	-5.63B 38.73%	-21.36B 279.26%
cost and expenses	288.83B -	297.27B 2.92%	320.55B 7.83%	311.38B 2.86%	291.17B 6.49%	287.74B 1.18%	250.45B 12.96%	259.36B 3.56%	291.14B 12.25%	316.00B 8.54%	346.39B 9.62%
operating expenses	160.98B -	169.73B 5.43%	181.62B 7.01%	176.85B 2.63%	162.11B 8.33%	168.40B 3.88%	170.83B 1.44%	178.92B 4.74%	203.29B 13.62%	229.08B 12.69%	224.78B 1.88%
interest expense	259M -	145M 44.02%	59M 59.31%	42M 28.81%	931M 2,116.67%	1.59B 71.21%	1.31B 17.69%	299M 77.21%	1.12B 273.58%	1.09B 2.60%	190M 82.54%
ebitda	83.93B -	67.86B 19.15%	75.63B 11.45%	64.71B 14.43%	78.81B 21.79%	97.25B 23.40%	64.60B 33.57%	73.03B 13.04%	80.67B 10.46%	87.14B 8.02%	116.94B 34.20%
operating income	51.77B -	36.17B 30.13%	43.77B 20.99%	31.64B 27.71%	57.73B 82.47%	75.03B 29.97%	45.80B 38.95%	52.56B 14.75%	61.17B 16.37%	68.66B 12.25%	95.84B 39.59%
depreciation and amortization	33.17B -	36.71B 10.68%	36.56B 0.41%	35.67B 2.43%	22.03B 38.24%	22.22B 0.86%	18.80B 15.41%	20.47B 8.88%	19.50B 4.73%	18.48B 5.24%	21.10B 14.18%
total other income expenses net	-2B -	-8.93B 346.40%	-2.37B 73.51%	-1.35B 42.92%	-1.88B 39.41%	-1.59B 15.30%	-1.31B 17.69%	-299M 77.21%	-1.12B 273.58%	-1.09B 2.60%	461M 142.37%
income before tax	49.77B -	27.25B 45.26%	41.40B 51.95%	30.29B 26.84%	55.85B 84.39%	73.44B 31.49%	44.49B 39.42%	52.26B 17.47%	60.05B 14.90%	67.57B 12.53%	96.30B 42.52%
income tax expense	19.60B -	11.35B 42.12%	11.63B 2.46%	11.62B 0.05%	12.95B 11.46%	19.02B 46.91%	6.82B 64.16%	5.24B 23.20%	7.70B 47.12%	14B 81.75%	16.06B 14.70%
net income	30.08B -	15.90B 47.14%	29.77B 87.28%	18.67B 37.30%	42.90B 129.79%	54.41B 26.84%	37.67B 30.76%	47.03B 24.83%	52.35B 11.31%	53.57B 2.34%	81.19B 51.55%
weighted average shs out	547.39M -	547.35M 0.01%	547.29M 0.01%	547.29M 0.00%	547.29M 0%	538.54M 1.60%	538.54M 0%	537.11M 0.27%	537.28M 0.03%	538.54M 0.24%	537.58M 0.18%
weighted average shs out dil	547.77M -	547.83M 0.01%	547.72M 0.02%	547.86M 0.03%	547.86M 0%	539.01M 1.62%	539.01M 0%	537.48M 0.28%	537.50M 0.00%	538.54M 0.19%	537.63M 0.17%
eps	54.95 -	29.05 47.13%	54.40 87.26%	55.65 2.30%	78.38 40.84%	101.04 28.91%	69.96 30.76%	87.56 25.16%	97.43 11.27%	99.48 2.10%	151.03 51.82%
epsdiluted	54.91 -	29.02 47.15%	54.36 87.32%	55.59 2.26%	78.30 40.85%	100.95 28.93%	69.89 30.77%	87.50 25.20%	97.39 11.30%	99.48 2.15%	151.01 51.80%

4151

COM:KYOWAKIRIN

Kyowa Kirin Co., Ltd.

Last Close

2,545.00

22/11 03:55

Market Cap

1.66T

Beta: -

Volume Today

459.30K

Avg: -

Preview